SU1692552A1 - Method for estimation of liver circulation in cardiosurgery patients - Google Patents
Method for estimation of liver circulation in cardiosurgery patients Download PDFInfo
- Publication number
- SU1692552A1 SU1692552A1 SU894768809A SU4768809A SU1692552A1 SU 1692552 A1 SU1692552 A1 SU 1692552A1 SU 894768809 A SU894768809 A SU 894768809A SU 4768809 A SU4768809 A SU 4768809A SU 1692552 A1 SU1692552 A1 SU 1692552A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- blood
- bromsulfalein
- blood flow
- minutes
- concentration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 6
- 210000004185 liver Anatomy 0.000 title 1
- GHAFORRTMVIXHS-UHFFFAOYSA-L bromosulfophthalein sodium Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(O)=CC=C1C1(C=2C=C(C(O)=CC=2)S([O-])(=O)=O)C(C(Br)=C(Br)C(Br)=C2Br)=C2C(=O)O1 GHAFORRTMVIXHS-UHFFFAOYSA-L 0.000 claims abstract description 10
- 230000017531 blood circulation Effects 0.000 claims abstract description 7
- 230000002440 hepatic effect Effects 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 238000007675 cardiac surgery Methods 0.000 abstract description 2
- RBDJQFKUZPMOFH-UHFFFAOYSA-I pentasodium;3-amino-4-[[4-[4-[(2-amino-3,6-disulfonatonaphthalen-1-yl)diazenyl]-3-sulfonatophenyl]phenyl]diazenyl]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(N)=C1N=NC1=CC=C(C=2C=C(C(N=NC=3C4=CC=C(C=C4C=C(C=3N)S([O-])(=O)=O)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)C=C1 RBDJQFKUZPMOFH-UHFFFAOYSA-I 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относитс к медицине, в частности к кардиологии и кардиохирургии, и может быть использовано в экспериментальной и клинической практике дл оценки состо ни печеночного кровотока. Цель изобретени - упрощение и ускорение способа , достигаетс за счет предварительного определени объема циркулирующей плазмы с помощью трипанового красного, значение которого вместе со значением остаточной дозы бромсульфалеина используют дл расчета печеночного кровотока.The invention relates to medicine, in particular cardiology and cardiac surgery, and can be used in experimental and clinical practice to assess the state of the hepatic blood flow. The purpose of the invention is to simplify and accelerate the method, achieved by preliminarily determining the volume of circulating plasma using trypan red, the value of which, together with the value of the residual dose of bromsulfalein, is used to calculate the hepatic blood flow.
Description
ЁYo
Изобретение относитс к медицине, в частности к кардиологии и кардиохирургии, и может быть использовано в экспериментальной и клинической практике дл оценки состо ни печеночного кровотока.The invention relates to medicine, in particular cardiology and cardiac surgery, and can be used in experimental and clinical practice to assess the state of the hepatic blood flow.
Цель изобретени - упрощение и ускорение способа.The purpose of the invention is the simplification and acceleration of the method.
Способ осуществл етс следующим образом .The method is carried out as follows.
Дл анализа образцы крови центрифугировали при 3000 об/мин в течение 15 мин, отдел ли плазму и хранили при комнатной температуре в течение 3-6 ч. Все образцы измер лись одновременно.For analysis, blood samples were centrifuged at 3000 rpm for 15 minutes, plasma was separated and stored at room temperature for 3-6 hours. All samples were measured simultaneously.
Определение объема циркулирующей плазмы (ОЦП) с помощью трипанового красного .Determination of circulating plasma volume (VCP) using trypan red.
В зависимости от введенной дозы и концентрации в крови рассчитываетс ОЦП. Препарат вводили из расчета 2 мг/кг массы животного. В контрольную и опытную пробу , содержащую по 1 мл сыворотки или плазмы крови, подавали по 2 мл 0.2N НС и фотометрировали при А 510 нм. По стандартной кривой зависимости концентрации препарата и оптической плотности определ ли содержание трипанрота в крови, ОЦП рассчитывали по формулеDepending on the dose administered and the concentration in the blood, an ORP is calculated. The drug was administered at the rate of 2 mg / kg animal mass. In the control and experimental sample, containing 1 ml of serum or plasma, 2 ml of 0.2N HC each were fed and photometric at А 510 nm. The concentration of trypanrota in the blood was determined from the standard curve of the concentration of the drug and optical density, the CPV was calculated by the formula
ОЦП Јl,Open cpl
LT где Дт - доза введенного препарата (мг);LT where Dt is the dose of the drug administered (mg);
Ст - концентраци препарата в крови (мг/л).St - concentration of the drug in the blood (mg / l).
Определение остаточной дозы бромсульфалеина .Determination of the residual dose of bromsulfalein.
Через 10 мин после введени препарата в локтевую вену в дозе 5 мг/кг в контрольную и опытную пробу крови, содержащих по 1 мл сыворотки или плазмы крови, вносили по 2 мл 0,2N NaOH и фотометрировали при А 580 нм. По стандартной кривой зависимости оптической плотности от концентраО10 minutes after administration of the drug into the cubital vein at a dose of 5 mg / kg, 2 ml of 0.2N NaOH was added to a control and experimental blood sample containing 1 ml of serum or plasma, and was photometric at А 580 nm. According to the standard curve of the dependence of optical density on concentration
ю ю ел ел юyu ate yu yu
ции препарата находили содержание бром- сульфалеина в крови. Остаточную дозу бромсульфалеина в крови определ ли по формулеthe drug was found to contain bromosulfalein in the blood. The residual dose of bromsulfalein in the blood was determined by the formula
ОД СбхОЦП,OD SbHOTsP,
где ОД - остаточна доза бромсульфалеииа в крови (мг);where OD is the residual dose of bromsulphalia in the blood (mg);
Сб - концентраци бромсульфалеина в крови (мг/л).Sat is the concentration of bromsulfalein in the blood (mg / l).
Рассчитывали процент остаточной дозы (ОД %):Calculated the percentage of residual dose (OD%):
ОД% хЮО%, ДбOD% xUO%, dB
где ОД % - процент остаточной дозы;where OD% is the percentage of residual dose;
Дб - введенна доза бромсульфалеина; DB - injected dose of bromsulfalein;
ОД - остаточна доза бромсульфалеина .OD - residual dose of bromsulfalein.
Вычисл ли логарифм ОД %.Calculated whether the log OD%.
По уравнению определ ли печеночный кровоток:Hepatic blood flow is determined by the equation:
2,288-Y2,288-Y
X0 ,025X0,025
где X - показатель печеночного кровотока мл/кг веса в 1 мин;where X is an indicator of hepatic blood flow ml / kg of body weight per 1 min;
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894768809A SU1692552A1 (en) | 1989-12-15 | 1989-12-15 | Method for estimation of liver circulation in cardiosurgery patients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894768809A SU1692552A1 (en) | 1989-12-15 | 1989-12-15 | Method for estimation of liver circulation in cardiosurgery patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1692552A1 true SU1692552A1 (en) | 1991-11-23 |
Family
ID=21484498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU894768809A SU1692552A1 (en) | 1989-12-15 | 1989-12-15 | Method for estimation of liver circulation in cardiosurgery patients |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1692552A1 (en) |
-
1989
- 1989-12-15 SU SU894768809A patent/SU1692552A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Фишер А. Физиологи и экспериментальна патологи печени. - Будапешт. 1961, с. 40-46. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency | |
| US5091304A (en) | Whole blood activated partial thromboplastin time test and associated apparatus | |
| Zade‐Oppen | Posthypertonic hemolysis in sodium chloride systems | |
| Wilkins et al. | Immunologically mediated thrombocytopenia in the dog | |
| Congdon et al. | Monitoring heparin therapy in hemodialysis: A report on the activated whole blood coagulation time tests | |
| Green et al. | A study of the variable response of human platelets to collagen: relation to aspirin-induced inhibition of aggregation | |
| US5181518A (en) | Method of evaluating cardioprotective agents | |
| Eika et al. | Low incidence of thrombocytopenia during treatment with hog mucosa and beef lung heparin | |
| Ingeberg et al. | Platelet aggregation and release of ATP in patients with hepatic cirrhosis | |
| Pignatelli et al. | Acid citrate dextrose (ACD) formula A as a new anticoagulant in the measurement of in vitro platelet aggregation | |
| SU1692552A1 (en) | Method for estimation of liver circulation in cardiosurgery patients | |
| Heinrich et al. | Cryofibrinogen: formation and inhibition in heparinized plasma | |
| Jähnchen et al. | Determination of phenylbutazone in plasma | |
| Ring et al. | Cigarette smoking shortens the bleeding time | |
| Sahud et al. | Utilization of ascorbic acid during platelet aggregation | |
| Elmér et al. | Ethanol-induced microaggregate formation in pig and rabbit blood | |
| Brigham et al. | [14C] urea and [14C] sucrose as permeability indicators in histamine pulmonary edema | |
| Jaenike et al. | The relative volumes of distribution of I131-tagged albumin and high molecular weight dextran in normal subjects and patients with heart disease | |
| JP2954239B2 (en) | Simple blood coagulation test equipment for whole blood | |
| CA1136030A (en) | Method and apparatus for collecting blood samples | |
| Robbins | Effects of phenyl benzo-γ-pyrone derivatives (flavonoids) on blood cell aggregation: basis for a concept of mode of action | |
| US5318910A (en) | Standard whole blood composition for determining the potency of blood clotting inhibitory substances | |
| Raisz et al. | A comparison of efficacy of dextran, oxypolygelatin, plasma and saline as plasma volume expanders | |
| RU2152615C1 (en) | Method for predicting acute period outcome of burn disease | |
| RU2188419C2 (en) | Method for studying anti-aggregation action of preparations by determining blood platelet aggregation in vitro |